RDMD, which has partnered with Cure Sanfilippo Foundation and other select patient advocacy groups, announced it has raised $14 million in Series A financing to continue its work to accelerate rare disease research and drug development.
RDMD has developed an FDA-ready technology platform that generates deep clinical evidence to accelerate rare disease research and drug development through a patient application that empowers patients and families to participate in research from home.
The $14 million will be used to:
- Expand into 20 additional rare diseases
- Launch corresponding research studies for each of the new conditions, which will help researchers better understand the natural progression of each disease and design better trials as a result
- Offer new and improved research experience and research insights to participants in each rare disease community
- Expand the company’s collaborative partnerships with patient organizations and academic consortiums ready to build a regulatory-grade evidence platform in their conditions
- Grow the company’s commercial partnerships with new and existing biopharmaceutical customers
- Further expand the company’s international platform capabilities
- Expand the company’s team, including key senior leadership hires
- Ensure continuity of research programs throughout the COVID-19 pandemic and beyond
Partnership With Cure Sanfilippo Foundation
Cure Sanfilippo Foundation is the first patient advocacy organization focused on Sanfilippo Syndrome to collaborate with RDMD and use the technology’s horsepower to support research for a treatment and cure.
Cure Sanfilippo Foundation collaborated with RDMD on a poster presentation for research scientists, biotech leads and industry partners, physicians, U.S. Food & Drug Administration (FDA) staff, and patient advocates at the WORLD Symposium 2020, a conference regarding lysosomal storage diseases held this past February.
“RDMD gathered more than 7,000 medical records from hospitals across the U.S. and Canada for our Sanfilippo community, and their research team generated meaningful insights to produce a research poster within months,” said Dr. Cara O’Neill, Chief Science Officer of the Cure Sanfilippo Foundation. “The best part is that patients didn’t have to pick up the phone to call their hospitals once – RDMD did all the legwork behind the scenes.”
Some of the information shared in the poster presentation:
